File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Early growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-flurorouracil on nasopharyngeal carcinoma

TitleEarly growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-flurorouracil on nasopharyngeal carcinoma
Authors
Keywords5-Fu
Egr-1
Gene Therapy
Htertc27
Nasopharyngeal Carcinoma
Issue Date2012
PublisherMary Ann Liebert, Inc Publishers. The Journal's web site is located at http://www.liebertpub.com/cbr
Citation
Cancer Biotherapy And Radiopharmaceuticals, 2012, v. 27 n. 7, p. 434-441 How to Cite?
AbstracthTERTC27 is a newly constructed polypeptide that can induce telomere dysfunction. To study the synergistic antitumor effects of the hTERTC27 polypeptide driven by the early growth response protein-1 (Egr-1) promoter and chemotherapeutic 5-flurorouracil (5-FU) on nasopharyngeal carcinoma, a series of in vitro and in vivo experiments were performed. The results showed that hTERTC27 expression was significantly increased up to 7.21-folds by the 5-FU-activated Egr-1 promoter in C666-1 cells. Overexpressed hTERTC27 made the cells more sensitive to 5-FU, and additionally, inhibited cell proliferation about 20.41%. Combinational therapy of overexpressed hTERTC27 driven by the 5-FU-activated Egr-1 promoter and 5-FU synergistically inhibited cell proliferation and promoted apoptosis of C666-1 cells for about 4.75-fold and 1.76-fold in comparison with a sole therapy of hTERTC27 or 5-FU in vitro. In vivo experiments showed that overexpressed hTERTC27 driven by 5-FU-activated Egr-1 promoter and 5-FU synergistically reduced tumor volume, tumor weight, and local infiltration, which may be relative to tumor cell apoptosis. These results suggest that combinational therapy of overexpressed hTERTC27, which is driven by the 5-FU-activated Egr-1 promoter, and 5-FU may provide a novel approach to treat nasopharyngeal cancer. © 2012 Mary Ann Liebert, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/179309
ISSN
2015 Impact Factor: 1.715
2015 SCImago Journal Rankings: 0.637
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLin, Gen_US
dc.contributor.authorLin, MCMen_US
dc.contributor.authorLin, Sen_US
dc.contributor.authorYao, Hen_US
dc.contributor.authorYu, Sen_US
dc.contributor.authorYi, Wen_US
dc.contributor.authorXu, Gen_US
dc.contributor.authorNg, SSMen_US
dc.contributor.authorChen, Sen_US
dc.contributor.authorYu, Jen_US
dc.contributor.authorWang, Xen_US
dc.contributor.authorYang, Ben_US
dc.date.accessioned2012-12-19T09:54:02Z-
dc.date.available2012-12-19T09:54:02Z-
dc.date.issued2012en_US
dc.identifier.citationCancer Biotherapy And Radiopharmaceuticals, 2012, v. 27 n. 7, p. 434-441en_US
dc.identifier.issn1084-9785en_US
dc.identifier.urihttp://hdl.handle.net/10722/179309-
dc.description.abstracthTERTC27 is a newly constructed polypeptide that can induce telomere dysfunction. To study the synergistic antitumor effects of the hTERTC27 polypeptide driven by the early growth response protein-1 (Egr-1) promoter and chemotherapeutic 5-flurorouracil (5-FU) on nasopharyngeal carcinoma, a series of in vitro and in vivo experiments were performed. The results showed that hTERTC27 expression was significantly increased up to 7.21-folds by the 5-FU-activated Egr-1 promoter in C666-1 cells. Overexpressed hTERTC27 made the cells more sensitive to 5-FU, and additionally, inhibited cell proliferation about 20.41%. Combinational therapy of overexpressed hTERTC27 driven by the 5-FU-activated Egr-1 promoter and 5-FU synergistically inhibited cell proliferation and promoted apoptosis of C666-1 cells for about 4.75-fold and 1.76-fold in comparison with a sole therapy of hTERTC27 or 5-FU in vitro. In vivo experiments showed that overexpressed hTERTC27 driven by 5-FU-activated Egr-1 promoter and 5-FU synergistically reduced tumor volume, tumor weight, and local infiltration, which may be relative to tumor cell apoptosis. These results suggest that combinational therapy of overexpressed hTERTC27, which is driven by the 5-FU-activated Egr-1 promoter, and 5-FU may provide a novel approach to treat nasopharyngeal cancer. © 2012 Mary Ann Liebert, Inc.en_US
dc.languageengen_US
dc.publisherMary Ann Liebert, Inc Publishers. The Journal's web site is located at http://www.liebertpub.com/cbren_US
dc.relation.ispartofCancer Biotherapy and Radiopharmaceuticalsen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject5-Fuen_US
dc.subjectEgr-1en_US
dc.subjectGene Therapyen_US
dc.subjectHtertc27en_US
dc.subjectNasopharyngeal Carcinomaen_US
dc.titleEarly growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-flurorouracil on nasopharyngeal carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailLin, MCM: mcllin@hkucc.hku.hken_US
dc.identifier.emailNg, SSM: ssmng@hku.hken_US
dc.identifier.authorityLin, MCM=rp00746en_US
dc.identifier.authorityNg, SSM=rp00767en_US
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1089/cbr.2011.1153en_US
dc.identifier.pmid22947087-
dc.identifier.scopuseid_2-s2.0-84866280585en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84866280585&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issue7en_US
dc.identifier.spage434en_US
dc.identifier.epage441en_US
dc.identifier.isiWOS:000308698800006-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLin, G=9250912200en_US
dc.identifier.scopusauthoridLin, MCM=7404816359en_US
dc.identifier.scopusauthoridLin, S=55355116500en_US
dc.identifier.scopusauthoridYao, H=13104506400en_US
dc.identifier.scopusauthoridYu, S=55358912600en_US
dc.identifier.scopusauthoridYi, W=55359098500en_US
dc.identifier.scopusauthoridXu, G=55359053500en_US
dc.identifier.scopusauthoridNg, SSM=7403358718en_US
dc.identifier.scopusauthoridChen, S=13606526600en_US
dc.identifier.scopusauthoridYu, J=55359170300en_US
dc.identifier.scopusauthoridWang, X=55359236200en_US
dc.identifier.scopusauthoridYang, B=7404472409en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats